Details for Patent: 11,040,107
✉ Email this page to a colleague
Which drugs does patent 11,040,107 protect, and when does it expire?
Patent 11,040,107 protects EMPAVELI and is included in one NDA.
This patent has thirteen patent family members in eleven countries.
Summary for Patent: 11,040,107
| Title: | Dosing regimens and related compositions and methods |
| Abstract: | In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. |
| Inventor(s): | Grossi; Federico (Newton, MA), Deschatelets; Pascal (Lexington, MA), Francois; Cedric (Prospect, KY), Johnson; Patrick (Zurich, CH), Vega; Carolina (Berkeley, CA) |
| Assignee: | Apellis Pharmaceuticals, Inc. (Waltham, MA) |
| Application Number: | 16/500,994 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Delivery; Device; |
Drugs Protected by US Patent 11,040,107
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharms | EMPAVELI | pegcetacoplan | SOLUTION;SUBCUTANEOUS | 215014-001 | May 14, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN | ⤷ Sign Up | |||
| Apellis Pharms | EMPAVELI | pegcetacoplan | SOLUTION;SUBCUTANEOUS | 215014-001 | May 14, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN EVERY THREE DAYS | ⤷ Sign Up | |||
| Apellis Pharms | EMPAVELI | pegcetacoplan | SOLUTION;SUBCUTANEOUS | 215014-001 | May 14, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN TWICE WEEKLY | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,040,107
| PCT Information | |||
| PCT Filed | April 09, 2018 | PCT Application Number: | PCT/US2018/026753 |
| PCT Publication Date: | October 11, 2018 | PCT Publication Number: | WO2018/187813 |
International Family Members for US Patent 11,040,107
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018249627 | ⤷ Sign Up | |||
| Brazil | 112019020955 | ⤷ Sign Up | |||
| Canada | 3059304 | ⤷ Sign Up | |||
| China | 110831544 | ⤷ Sign Up | |||
| China | 116059313 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
